IVD MALDI Sepsityper workflow typically reduces Time-to-Result (TTR) for sepsis by 24 to 36 hours for over 2,000 bacterial and over 200 yeast species, while retaining all the advantages of blood cultures
COPENHAGEN, Denmark--(BUSINESS WIRE)-- At the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker announced the introduction of the new IVD MALDI SepsityperTM kit and workflow with standard operating procedures for the rapid identification of microorganisms from positive blood culture bottles. The IVD kit is now labeled according to the European IVD directive EC/98/79, and is developed for use with the IVD MALDI Biotyper (IVD MBT) system for rapid MALDI-TOF mass spectrometry-based microbial identification.
The IVD MALDI Sepsityper kit enables a rapid and easy isolation and identification of microorganisms within minutes from positive blood culture bottles. Harvested microorganisms are processed and then identified using the IVD MALDI Biotyper. The identification assay from positive blood cultures is applicable to Gram-negative and Gram-positive bacteria, as well as to yeast. The IVD MALDI Biotyper reference library covers more than 2,000 different bacteria species and approximately 200 species of yeasts, including candida. This workflow is recommended and optimized for blood culture bottles without any charcoal supplements.
Overall, the IVD MALDI Sepsityper workflow takes approximately 30 minutes after gram-staining and extraction from a positive blood culture bottle to identification. It saves the day normally required for additional agar plate culturing, and it can also save an additional 8-12 hours, when compared to traditional biochemical identification after agar plate culturing.
Sepsis is a life-threatening condition with high mortality rates. Published studies have shown that each hour of delay in initiating effective antibiotic therapy can increase mortality significantly. Due to this high risk, and based on current sepsis guidelines, therapy is typically initiated using broad-spectrum antibiotics to maximize the probability of antibiotic coverage of the potential pathogen, with the goal of either de-escalating therapy to a more narrow antibiotic, or to switch antibiotic or antifungal therapy, based on laboratory findings.
The IVD MALDI Sepsityper workflow reduces the turnaround time provided by traditional workflows by typically 24 to 36 hours after a blood culture bottle becomes positive. The faster results provided by the IVD MALDI Sepsityper workflow aid the clinician in the management of blood stream infections. These earlier identification results, combined with antibiotic stewardship programs, can reduce healthcare costs substantially, and can improve patient outcomes, while also assisting in the fight against antibiotic resistance via reductions in the use of ineffective or expensive antibiotics. In contrast to pure nucleic acid amplification test (NAATs), blood cultures do not amplify biologically non-active DNA or cells, but only the most active and relevant microbial species. Moreover, the IVD MALDI Sepsityper workflow is untargeted and offers very broad microbial coverage of gram-negative and gram-positive bacterial species, as well as clinically relevant yeast species, including candida.
Dr. Cassie Pope, Consultant Clinical Scientist from St. George’s Hospital in London, UK, said: “The introduction of the Bruker MALDI Sepsityper kit into our workflow has proved to be a decision that we are very pleased with, and that has resulted in clear benefits to the laboratory and our users. We implemented it for the identification of organisms in all blood cultures that have flagged as positive in the morning. This has reduced our time to identification by 24 hours, and allows us to provide a better service, and promotes timely prescription of appropriate narrow spectrum antimicrobials. This is valued by clinicians and they are now used to the improved service and earlier identification information. Our scientific staff enjoys using the kit, as it is easy to perform and provides identifications that they have confidence in, typically within 30 minutes.”
Dr. Nils Morgenthaler, Vice President for Medical Affairs for the Bruker Daltonics Division, added: “We and our collaborators now have several years of experience with the research-use-only (RUO) MALDI Sepsityper workflow, and the feedback from our customers and collaborators has been very positive. So far, 21 peer reviewed scientific publications have evaluated this approach, in which the RUO MALDI Sepsityper workflow has been shown to provide approximately 80% correct identification at the species level, with the remaining 20% mostly unidentified, and with essentially no relevant misidentifications at the genus level. With further recent improvements and expansion in the IVD MALDI Biotyper reference library, this already excellent identification performance directly from blood culture is expected to improve even further. The recent CE-labeling of the kit underlines Bruker´s strategy to provide more and more workflows for clinical routine use on the IVD MALDI Biotyper platform. We believe that the IVD MALDI Sepsityper kit and workflow has the potential to rapidly become the new gold standard in microorganism identification in clinical microbiology directly out of positive blood cultures, due to its very short TTR and broad bacteria and yeast species coverage.”
About the Bruker MALDI Biotyper Platform
The MALDI Biotyper family of systems enables molecular identification, and taxonomical classification or de-replication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. The MALDI Biotyper uses a molecular approach based on specific proteomic fingerprints from bacterial strains and published studies have highlighted the greater accuracy and lower cost offered, as well as the much faster time-to-result (TTR).
Applications of the various MALDI Biotyper solutions include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. In many European and international laboratories the MALDI Biotyper has replaced classical biochemical testing for bacterial identification in the past seven years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system. Classical biochemical techniques detect different metabolic properties of microorganisms, can take many hours or even days for completion, and they often lack specificity.
The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The products of the MALDI Biotyper family are available in a research-use-only (RUO) version, as the U.S. FDA-cleared MALDI Biotyper CA System, or in an IVD-CE version according to EU directive EC/98/79. The MALDI Biotyper also has medical device registrations in numerous other countries. RUO versions of the MALDI Biotyper even allow selected high-value antimicrobial resistance tests in translational research.
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, www.bruker.com.
Vice President of Investor Relations
T: +1 978 663 3660 ext.1479
Bruker Daltonics Division
Dr. Winfried Busch